119
{"meta":"{\"title\":\"The Swiss Center for Musculoskeletal Biobanking is participating in the NISCI study.\",\"subtitle\":\"The Swiss Center for Musculoskeletal Biobanking is participating in the NISCI study.\",\"abstract\":\"\",\"description\":\"The purpose of the NISCI (Nogo Inhibition in Spinal Cord Injury) study is to test whether antibody therapy can improve movement and quality of life in quadriplegics.\",\"keywords\":\"\",\"canonical\":\"\",\"robots\":{\"noIndex\":false,\"noFollow\":false},\"author\":\"\",\"authorEmail\":\"\",\"ogTitle\":\"NISCI \\u2013 Nogo Inhibition in Spinal Cord Injury\",\"ogDescription\":\"The purpose of the NISCI (Nogo Inhibition in Spinal Cord Injury) study is to test whether antibody therapy can improve movement and quality of life in quadriplegics.\",\"twitterTitle\":\"NISCI \\u2013 Nogo Inhibition in Spinal Cord Injury\",\"twitterDescription\":\"The purpose of the NISCI (Nogo Inhibition in Spinal Cord Injury) study is to test whether antibody therapy can improve movement and quality of life in quadriplegics.\",\"twitterCard\":\"summary\",\"ogImage\":\"\",\"twitterImage\":\"\"}","data":"{\"id\":119,\"type\":\"Standard\",\"slug\":\"\\\/reports\\\/success-stories\\\/nisci-nogo-inhibition-in-spinal-cord-injury\",\"media\":[],\"categories\":\"\",\"breadcrumbs\":[{\"title\":\"Balgrist Campus\",\"link\":\"\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"Facts, Figures & Visuals\",\"link\":\"\\\/facts-figures\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"Publications & Reports\",\"link\":\"\\\/reports\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"Success Stories\",\"link\":\"\\\/reports\\\/success-stories\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"NISCI \\u2013 Nogo Inhibition in Spinal Cord Injury\",\"link\":\"\\\/reports\\\/success-stories\\\/nisci-nogo-inhibition-in-spinal-cord-injury\\\/\",\"target\":\"\",\"active\":1,\"current\":1,\"spacer\":0,\"hasSubpages\":0}],\"appearance\":{\"layout\":\"layout-0\",\"backendLayout\":\"default\"}}"}
Publications & Reports >
Success Stories >
NISCI – Nogo Inhibition in Spinal Cord Injury
NISCI – Nogo Inhibition in Spinal Cord Injury
The Swiss Center for Musculoskeletal Biobanking is participating in the NISCI study.
The purpose of the NISCI (Nogo Inhibition in Spinal Cord Injury) study is to test whether antibody therapy can improve movement and quality of life in quadriplegics.
Spinal cord injury is mainly caused by work, traffic, and sports accidents, as well as violence. Paraplegia (leg and autonomic function affected) and tetraplegia (leg, arm and autonomic function affected; possibly combined with the need for artificial respiration) affect the quality of life and the ability to work of the majority of patients in a severe and dramatic way. The social and economic burden of lifelong care is enormous.
Regeneration of nerve fiber breaks are extremely limited, a phenomenon that is a major reason for low recovery after SCI.
One of the most potent inhibitors of neurite growth molecules is Nogo-A, a membrane protein that comprises multiple inhibitory domains.
In vitro work has shown that monoclonal antibodies to Nogo-A neutralize the inhibitory activity of purified or recombinant Nogo-A. More importantly, a series of publications over more than 15 years have shown that the use of anti-Nogo-A antibodies produces significant improvements in functional recovery in rodent models of SCI.
A previous study has shown that this treatment is safe and well tolerated. The NISCI study is now designed to demonstrate whether anti-Nogo-A antibody therapy can improve body function and quality of life in human quadriplegics.
« Communication and cooperation with the SCMB staff is easy, straightforward and very professional. »
Center for Paraplegia, Balgrist University Hospital
More information can be found at:
clinicaltrials.gov
nisci-2020.eu
The NISCI study is led by Prof. Dr. Armin Curt (University of Zurich / Balgrist University Hospital) and Prof. Dr. Norbert Weidner (Heidelberg University Hospital).